Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Neupro is a prescription transdermal patch containing rotigotine, a dopamine agonist. It is approved for the treatment of Parkinson's disease and moderate to severe primary restless legs syndrome. The patch delivers medication through the skin over a 24-hour period. Neupro helps control symptoms associated with altered dopamine signaling but does not cure either condition.
read more about neupro ...Neupro contains rotigotine, which activates dopamine receptors in the brain and nervous system. Dopamine helps regulate movement and other neurological functions. In Parkinson's disease, reduced dopamine activity contributes to movement symptoms such as stiffness, slowness, and tremor. Rotigotine stimulates dopamine receptors to help control these symptoms. In restless legs syndrome, dopamine receptor activity can help reduce the urge to move the legs and associated discomfort.
Neupro is used for Parkinson's disease, including early-stage and advanced-stage disease. It can help manage symptoms such as muscle stiffness, tremor, and slowed movement. Neupro is also prescribed for moderate to severe primary restless legs syndrome, which causes uncomfortable leg sensations and an urge to move, particularly during rest. Dosing differs between the two conditions, and treatment is individualized according to symptoms and tolerance.
Neupro patches are applied once daily to clean, dry, intact skin on the abdomen, thigh, hip, flank, shoulder, or upper arm. Remove the previous patch before applying a new one, and rotate application sites to reduce irritation. Starting doses and dose increases depend on whether treatment is for Parkinson's disease or restless legs syndrome. Avoid exposing the patch to direct heat, and remove it before magnetic resonance imaging or cardioversion. Do not stop treatment abruptly.
Common side effects include nausea, dizziness, sleepiness, vomiting, and skin reactions at the application site. Serious risks include sudden sleep episodes, hallucinations, low blood pressure upon standing, and compulsive behaviors such as excessive gambling or shopping. Neupro can also worsen involuntary movements in some patients with Parkinson's disease. Abrupt withdrawal can cause fever, confusion, muscle rigidity, or withdrawal symptoms. A clinician should supervise dose changes and discontinuation.
DailyMed - NEUPRO (rotigotine) transdermal system. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939e28c5-f3a9-42c0-9a2d-8d471d82a6e0. Date Accessed October 16, 2026.
Neupro. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/neupro. Date Accessed October 16, 2026.
Rotigotine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547939/. Date Accessed October 16, 2026.
Rotigotine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Rotigotine. Date Accessed October 16, 2026.
Rotigotine Transdermal Patch. MedlinePlus. https://medlineplus.gov/druginfo/meds/a607059.html. Date Accessed October 16, 2026.